InVivoMAb anti-mouse TSLP

The 28F12 monoclonal antibody reacts with mouse Thymic Stromal-Derived Lymphopoetin (TSLP). TSLP is a cytokine that is closely related to IL-7. TSLP is expressed predominantly by epithelial cells in the thymus, lung, skin, intestine, and tonsils, as well as stromal cells, mast cells, and dendritic cells. TSLP exerts its biological activities by binding to a heterodimeric receptor that consists of IL-7Rα and the TSLP receptor (TSLPR) chain. Expression of TSLP is regulated by NF-κB and can be induced by exposure to viral, bacterial, or parasitic products, inflammatory cytokines, and the Th2 cell–associated cytokines IL-4 and IL-13. TSLP has important roles in conditioning DCs to drive Th2 differentiation and its expression is increased in immunopathologies associated with dysregulated Th2 cell–type cytokine production, including atopic dermatitis and asthma. It has additionally been reported to promote antibody isotype class switching in B cells, to regulate the development of Foxp3+ Tregs in the human thymus, and to promote basophil hematopoiesis. The 28F12 antibody has been reported to inhibit the bioactivity of mouse TSLP in vivo and in vitro.